Prenetics Global (PRE) Corporate presentation summary

Growth trajectory and market positioning

• Achieved fastest growth in supplement sector, scaling monthly revenue from $0.4M to $17M in 19 months, representing a 42x increase and a 23% compounded monthly growth rate.

• FY 2025 revenue reached $60M, with FY 2026 guidance raised to $210M–$220M and projected FY 2027 revenue exceeding $400M.

• End-of-year ARR for FY 2026 projected at $300M, with a long-term vision to surpass $1B ARR by 2029.

• Current market share is modest, with significant whitespace in the $209B global dietary supplements market.

Financing structure and shareholder value

• Secured $1B non-dilutive growth capital from General Catalyst’s Customer Value Fund, with no equity dilution or debt obligations.

• Capital is deployed cohort-by-cohort, funding up to 70% of monthly marketing spend, with repayments tied to each cohort’s revenue performance.

• Repayment is self-liquidating, with no fixed schedule or covenants, and underperformance risk is borne by the capital provider.

• After payback plus premium, all recurring profits from each cohort accrue fully to the company.

Unit economics and business performance

• Blended gross profit to CAC across all cohorts is 1.44x, with mature cohorts achieving payback within 3–6 months.

• Gross margin improved to 64% in Q1 2026, indicating embedded upside in profitability.

• CAC increased 2.9x from Q1 2025 to Q1 2026, but new subscriber AOV also rose 2.5x, maintaining efficiency.

• Total of 248,536 customers acquired with $46.2M S&M spend, generating $66.7M cumulative gross profit.